MARKET

APTO

APTO

Aptose Bioscienc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.070
+0.020
+1.90%
After Hours: 1.110 +0.04 +3.74% 17:43 05/20 EDT
OPEN
1.060
PREV CLOSE
1.050
HIGH
1.090
LOW
1.025
VOLUME
116.33K
TURNOVER
0
52 WEEK HIGH
5.78
52 WEEK LOW
0.9000
MARKET CAP
98.69M
P/E (TTM)
-1.5854
1D
5D
1M
3M
1Y
5Y
Aptose to Hold KOL Event and Corporate Update Thursday, June 2nd
Clinical Updates for HM43239 and Luxeptinib Poster Presentation for HM43239 is Scheduled for June 10th at EHA2022 Hybrid Congress SAN DIEGO and TORONTO, May 12, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX...
GlobeNewswire · 05/12 14:00
--RBC Cuts Price Target on Aptose Biosciences to $6 From $7, Maintains Outperform Rating, Speculative Risk Qualifier
MT Newswires · 05/10 08:14
BRIEF-Aptose Biosciences Q1 Loss Per Share C$0.12
reuters.com · 05/09 21:16
Aptose Biosciences GAAP EPS of -$0.12 beats by $0.02
Aptose Biosciences press release (NASDAQ:APTO): Q1 GAAP EPS of -$0.12 beats by $0.02. "We expect our research and development expenses to be higher for the foreseeable future as we continue
Seekingalpha · 05/09 20:33
Aptose Biosciences Q1 EPS $(0.12) Beats $(0.15) Estimate
Aptose Biosciences (NASDAQ:APTO) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 20 percent. This is a 33.33 percent increase over losses of $(0.18) per share from
Benzinga · 05/09 20:21
Aptose Reports Results for the First Quarter 2022
Expands HM43239 dose cohort at 160 mg Headway with luxeptinib “G3” formulation in patients Conference call and webcast at 5:00 pm ET today SAN DIEGO and TORONTO, May 09, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: ...
GlobeNewswire · 05/09 20:01
Notable earnings after Monday's close
ADES, AGM, AIV, AKBA, ALCO, ALTO, AMC, AMPH, AMWL, ANGI, APPF, APTO, ARCT, AROC, ASLE, ASRT, ATER, AVIR, AZTA, BATL, BHF, BLFS, BLI, BLNK, BODY, OTCPK:BOWFF, BRMK, BRT, BW, BWXT,
Seekingalpha · 05/08 21:35
FDA Grants Fast Track designation To Aptose Biosciences for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation
Aptose Biosciences Inc. (NASDAQ: APTO) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to HM43239, an oral, myeloid kinome inhibitor, for the treatment of patients with relapsed or refractory (R/R) acute myeloi...
Benzinga · 05/04 12:41
More
No Data
Learn about the latest financial forecast of APTO. Analyze the recent business situations of Aptose Bioscienc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

28.57%Strong Buy
71.43%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average APTO stock price target is 8.57 with a high estimate of 13.00 and a low estimate of 3.000.
High13.00
Average8.57
Low3.000
Current 1.070
EPS
Actual
Estimate
-0.22-0.16-0.11-0.05
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 67
Institutional Holdings: 30.78M
% Owned: 33.37%
Shares Outstanding: 92.23M
TypeInstitutionsShares
Increased
11
1.03M
New
8
569.62K
Decreased
14
1.52M
Sold Out
13
2.72M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.64%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/President/Chief Executive Officer/Chief Accounting Officer/Director
William Rice
Senior Vice President
Rafael Bejar
Other
Philippe Ledru
Lead Director/Independent Director
Denis Burger
Independent Director
Carol Ashe
Independent Director
Erich Platzer
Independent Director
Mark Vincent
Independent Director
Warren Whitehead
No Data
No Data
About APTO
Aptose Biosciences Inc. is a clinical-stage biotechnology company that is focused on discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company has two clinical-stage investigational products for hematologic malignancies: luxeptinib and APTO-253. The luxeptinib is a mutation agnostic Bruton’s tyrosine kinase (BTK) kinase inhibitor, which is in a Phase I a/b trial in patients with refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies and is in a separate Phase I a/b trial in patients with refractory acute myeloid leukemia (AML). Its APTO-253 is the clinical stage agent that directly targets the Master Regulator of Cell Cycle Entry and Proliferative Metabolism (MYC) oncogene and suppresses its expression, which is in a Phase I a/b clinical trial for the treatment of patients with relapsed.

Webull offers kinds of Aptose Biosciences Inc stock information, including NASDAQ:APTO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APTO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading APTO stock methods without spending real money on the virtual paper trading platform.